Effect of genetic polymorphism +294T/C in peroxisome proliferator-activated receptor delta on the risk of ischemic stroke in a Tunisian population

Journal of Molecular Neuroscience

Volumn 50, Issue 2, 2013, Pages 360-367

  Chehaibi, Khouloud ^a   Hrira, Mohamed Yahia ^b   Rouis, Mustapha ^c   Najah, Mohamed ^a   Jguirim Souissi, Imen ^a   Nouira, Samir ^d   Slimane, Mohamed Naceur ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c SORBONNE UNIVERSITÉ   (France)

^d FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

Diabetes; Ischemic stroke; Polymorphism; PPAR

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; TRIACYLGLYCEROL BLOOD LEVEL; TUNISIA;

AGED; ALLELES; BODY MASS INDEX; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR DELTA; STROKE; TRIGLYCERIDES; TUNISIA;

EID: 84878221895     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-9997-4     Document Type: Article

References (55)

1. Aberle J, Hopfer I, Beil FU, Seedorf U (2006a) Association of the T + 294C polymorphism in PPAR d with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 3:108-111
2. Aberle J, Hopfer I, Beil FU, Seedorf U (2006b) Association of peroxisome proliferator-activated receptor delta + 294 T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 30:1709-1713
3. Allen CL, Bayraktutan U (2008) Risk factors for ischaemic stroke. Int J Stroke 3:105-116
4. Arsenijevic D, de Bilbao F, Plamondon J et al (2006) Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor β-deficient mice. J Cereb Blood Flow Metab 26:433-445
5. Barak Y, Liao D, He W, Ong ES et al (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308
6. Barish GD, Atkins AR, Downes M et al (2008) PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis. PNAS 105:4271-4276
7. Burch LR, Donnelly LA, Doney ASF et al (2010) Peroxisome Proliferator-Activated Receptor-delta Genotype Influences Metabolic Phenotype and May Influence Lipid Response to Statin Therapy in Humans: A Genetics of Diabetes Audit and Research Tayside Study. J Clin Endocrinol Metab 95:1830-1837
8. Cardon LR, Palmer LJ (2003) Population stratification and spurious allelic association. Lancet 361:598-604
9. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM, Marian AJ (2004) Effects of PPARa, g and d haplotypes on plasma levels of lipids and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenet 14:61-71
10. Colhoun HM, McKeigue PM, Davey SG (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872
11. Dichgans M (2007) Genetics of ischaemic stroke. Lancet Neurol 6:149-161
12. Dressel U, Allen TL, Pippal JB, Rohde PR et al (2003) The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17:2477-2493
13. Flossmann E, Schulz UG, Rothwell PM (2004) Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 35:212-227
14. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. ClinChem 18:499-502
15. Gilde AJ, van der Lee KA, Willemsen PH et al (2003) Peroxisome proliferator-activated receptor (PPAR) aandPPARb/d, but not PPARg, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518-524
16. Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W (2005) The peroxisome proliferator-activated receptor delta +294 T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183:336-341
17. Grarup N, Albrechtsen A, Ek J et al (2007) Variation in the PPAR delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 50:1201-1208
18. Hankey GJ (2006) Potential new risk factors for ischemic stroke: what is their potential? Stroke 37:2181-2188
19. Hu C, Jia W, Fang Q et al (2006) Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet Med 23(12):1307-1312
20. Iadecola C, Davisson RL (2008) Hypertension and cerebrovascular dysfunction. Cell Metab 7:476-484
21. Iwashita A, Muramatsu Y, Yamazaki T et al (2007) Neuroprotective efficacy of the peroxisome proliferators-activated receptor delta selective agonists in vitro and in vivo. J Pharmacol Exp Ther 320:1087-1096
22. Jguirim-Souissi I, Jelassi A, Hrira Y et al (2010) + 294 T/C polymorphism in the PPAR- d gene is associated with risk of coronary artery disease in normolipidemic Tunisians. Genet Mol Res 9:1326-1333
23. Kim HJ, Kim MY, Jin et al (2009) Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/ Smad3. Circ Res 105:16-24
24. Kirshner HS (2009) Differentiating ischemic stroke subtypes: risk factors and secondary prevention. J Neurol Sci 279:1-8
25. Lee CH, Chawla A, Urbiztondo N et al (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302:453-457
26. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J et al (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 473:333-336
27. Liou JY, Lee S, Ghelani D et al (2006) Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 26:1481-1487
28. Lu L, Wu Y, Qi Q et al (2012) Associations of Type 2 Diabetes with Common Variants in PPARD and the Modifying Effect of Vitamin D among Middle-Aged and Elderly Chinese. PLoS One 7(4):e34895
29. Michalik L, Desvergne B, Tan NS et al (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta mutant mice. J Cell Biol 154:799-814
30. Nikitin AG, Chistiakov DA, Minushkina LO, Zateyshchikov DA, Nosikov VV (2010) Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. Hear Vessel 25:229-236
31. Oliver WR, Shenk JL, Snaith MR et al (2001) A selective peroxisome proliferator-activated receptor d agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311
32. Peters JM, Lee SS, Li W et al (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 20:5119-5128
33. Pialat JB, Cho TH, Beuf O et al (2007) MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. NMR Biomed 20:335-342
34. Piqueras L, Reynolds AR, Hodivala-Dilke KM et al (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63-69
35. Rival Y, Beneteau N, Taillandier T et al (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143-151
36. Robitaille J, Gaudet D, Perusse L, Vohl MC (2006 Sep 5). Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta - 87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond)
37. Robitaille J, Gaudet D, Pérusse L, Vohl MC (2007) Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator activated receptor-delta - 87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 31:411-417
38. Schulz UG, Rothwell PM (2003) Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 34:2050-2059
39. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99:2613-2618
40. Shin HD, Park BL, Kim LH et al (2004) Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 53(3):847-851
41. Skogsberg J, Kannisto K, Roshani L et al (2000) Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med 6:73-81
42. Skogsberg J, Kannisto K, Cassel TN, Hamsten A et al (2003a) Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637-643
43. Skogsberg J, McMahon AD, Karpe F, Hamsten A et al (2003b) Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 254:597-604
44. Tan NS, Michalik L, Noy N, Yasmin R et al (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15:3263-3277
45. Tan NS, Michalik L, Di-Poi N, Desvergne B et al (2004) Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing. Biochem Soc Trans 32:97-102
46. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus ADA (1998) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 22(Suppl. 1):S5-S19
47. Villegas R, Williams S, Gao Y et al (2011) Variation and type 2 diabetes in middle age Chinese women. Ann Hum Genet 75(5):621-629
48. Vosper H, Patel L, Graham TL et al (2001) The peroxisome proliferator-activated receptor- promotes lipid accumulation in human macrophages. J Biol Chem 276:44258-44265
49. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR et al (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2(10):294
50. Wei X-L, Yin R-X, Miao L, Wu D-F (2011) The peroxisome proliferator-activated receptor delta +294T>C polymorphism and alcohol consumption on serum lipid levels. Lipids Health Dis 10:242
51. Welch JS, Ricote M, Akiyama TE et al (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A 100:6712-6717
52. Yilmaz-Aydogan H, Kurnaz O, Kurt O et al (2011) Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem 358:355-363
53. YIlmaz-Aydogan H, Kucukhuseyin O, Kurnaz O et al (2012) Investigation of polymorphic variants of PPARD and APOE Genes in Turkish Coronary Heart Disease Patients. DNA Cell Biol 31:867-875
54. Yin KJ, Deng Z, Hamblin M et al (2010) Peroxisome proliferator-activated receptor delta regulation of mir-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci 30:6398-6408
55. Yin KJ, Zhen D, Milton H, Jifeng Z, Chen EY (2011) Vascular PPARδ protects against stroke-induced brain injury. Arterioscler Thromb Vasc Biol 31:574-581